Glycomimetics Inc. buy tamam
Zusammenfassung
Diese Einschätzung wurde am 12.12.17 mit einem Endkurs von 16,08 € beendet. Signifikant aufwärts ging es für die BUY Einschätzung von tamam zu Glycomimetics Inc. mit einer Rendite von 57,88 %. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Glycomimetics Inc. | -5,99 % | -5,99 % | -82,89 % | -85,77 % |
iShares Core DAX® | 0,79 % | -0,43 % | 17,46 % | 17,62 % |
iShares Nasdaq 100 | 2,30 % | 7,33 % | 38,19 % | 53,44 % |
iShares Nikkei 225® | 3,08 % | 3,28 % | 13,17 % | 10,19 % |
iShares S&P 500 | 0,90 % | 3,97 % | 29,79 % | 46,28 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Glycomimetics Inc. diskutieren
GlycoMimetics Is An Exceptional Investment Opportunity
GMI-1271 shows impressive efficacy and safety profile (as of interim Phase 2).
Recent mixed shelf offering hints at major near-term upside potentials.
Longer term, GLYC seems to have found an important biomarker (E-selectin) that may expand TAM exponentially.
FDA Breakthrough Designation will expedite the development process.
Smart institutional investors are behind GLYC as significant long-term investors.
For the longer term, GLYC seems to have found an important biomarker that will allow it to expand into multiple tumor types (key opportunity is multiple myeloma - second largest blood cancer market) - significantly expanding its TAM. This will attract many players in oncology to partner/acquire GLYC once the company proves to be important in AML. In fact, GLYC is already running a Phase 1 trial inmultiple myeloma with GMI-1271 and management has started talking about this opportunity.Der Beitrag wurde gelöscht